Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
Sanofi SA (NASDAQ:SNY) agreed to make a $27 million strategic investment in Ventyx Biosciences Inc (NASDAQ:VTYX). “We look ...
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.
bovnews2d
Ventyx Biosciences Inc (VTYX) Stock Dive: The Hidden Causes Revealed
Ventyx Biosciences Inc (VTYX) stock saw a decline, ending the day at $2.3 which represents a decrease of $-0.07 or -2.95% from the prior close of $2.37. The stock opened at $2.34 and touched a low of ...
Hosted on MSN6mon
Viking Therapeutics gains on early data for oral weight loss therapy
Other players in the obesity drug market include: Amgen (AMGN), Pfizer (PFE), AstraZeneca (AZN), Altimmune (ALT), vTv ...
Yahoo Finance6h
ATLANTIC SAPPHIRE TR (ASAT.OL)
It's another big week on Wall Street. The major indexes (^DJI,^GSPC, ^IXIC) are set to open higher, looking to build on last week's big gains. A number of Federal Reserve officials will speak about ...
bovnews6d
Ventyx Biosciences Inc (VTYX) Stock: More Robust Than the Numbers Suggest?
Ventyx Biosciences Inc (VTYX) stock saw a modest uptick, ending the day at $2.34 which represents a slight increase of $0.05 or 2.18% from the prior close of $2.29. The stock opened at $2.29 and ...
Ventyx Edges Forward on Parkinson’s Test Results
Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares enjoy slight gains Friday. The San Diego-based clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad ...